OVERVIEW & USAGE
Bryxta injection is a prescription drug. It is used in the treatment of patients with colorectal cancer, glioblastoma multiforme, renal cell carcinoma, cervical cancer, ovarian cancer, and other types of cancers. It can be prescribed either alone or in combination with other medications. This medicine can be used as a first-line treatment for certain cancers when used in combination. It comprises Bevacizumab, which is thought to be an effective regimen for the treatment of COVID-19 patients also. This medication works by hindering the growth of new blood vessels that are responsible for feeding the tumors. Through this mechanism, Bryxta stops the tumor’s growth. Bryxta (Bevacizumab) is available in the form of injections with strengths of 100mg and 400mg.
The active ingredient of Bryxta injection works to bind VEGF or circulating vascular endothelial-derived growth factor. Bevacizumab works by blocking it from binding to its consequent receptors while effectively blunting downstream signaling. The effects caused by this ingredient have been presented to re-establish normal vasculature at the tumor site that caused an increase in nutrient and oxygen supply. Bryxta injection also improves the delivery of chemotherapeutic agents to the target region. On the other hand, VEGF signaling is a critical constituent of different processes such as coagulation, healing of the wound, angiogenesis, regulation of BP, and renal filtration. Though blocking VEGF may cause inhibition of metastatic disease progression, it can also cause certain unwanted events because of the role of VEGF in various other physiologic mechanisms.
- Gastrointestinal perforation
- Abevmy 400mg Injection
- Krabeva 400mg Injection
- Bevacirel 400mg Injection
- Avastimab 400mg Injection
- Avastin 400mg Injection
Bryxta (Bevacizumab) injection should not be administered in the following cases:-
- A known allergy to Bevacizumab